Introduction {#sec1}
============

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second most common cause of cancer-related deaths \[[@B1]\]. In the past two decades, a marked increase in HCC-related annual death rates was observed \[[@B2],[@B4]\]. And, the incidence of HCC will continue to rise until 2030 based on a SEER registry projects study \[[@B5]\]. Previous research revealed that the prediction of prognosis plays a critical role in therapeutic options of HCC. But, little tumor markers have been externally validated in HCC survival prediction \[[@B6]\]. To find novel biomarkers for predicting HCC prognosis, and to reveal HCC target for treatment is urgently required.

As a characteristic of cancer, immune evasion is more prevalent in organs with high immune tolerance including the liver \[[@B7]\]. The sialic-acid-binding immunoglobulin-like lectins (siglecs), a novel family of immunoregulatory, have received more and more attention for their capacity to mediate cell death, anti-proliferative effects and to regulate a variety of cellular activities \[[@B8]\]. Currently, pharmacological strategies using siglec agonistic cross-linking therapeutics are discussed. Modulation of immune responses by targeting siglecs using agonistic or antagonistic therapeutics may have important clinical implications and may be a novel pharmacological strategy in tumor immunotherapy \[[@B8]\]. A recent research has revealed that high expression of siglec-10 on NK cells mediates impaired NK cell function, and siglec-10 expression in tumors is associated with poorer survival of HCC patients \[[@B9]\]. However, roles of siglec family in HCC development were little discussed.

According to the potential value of siglecs in HCC development, this study aimed to evaluate the associations between siglec family and outcomes from hepatitis B virus (HBV)-related HCC patients, hoping that the data may provide potential biomarker candidates and useful insights into the pathogenesis and progression of HCC.

Materials and methods {#sec2}
=====================

Patients {#sec2-1}
--------

Using GSE14520 profile from Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) database, 247 patients with HCC were identified. Twenty-seven patients were excluded for the unavailable siglec gene expression or insufficient clinical outcome data. Finally, 220 HCC cases were included in the analysis. All the HCC patients had a history of HBV infection or HBV-related liver cirrhosis; the diagnosis of HCC was made in all cases by two independent pathologists who had detailed information on clinical presentation and pathological characteristics as declared by Roessler et al. \[[@B10]\].

All liver tissue was obtained with informed consent from patients who underwent radical resection between 2002 and 2003 at the Liver Cancer Institute and Zhongshan Hospital, Fudan University. The study was approved by the Institutional Review Board of the participating institutes \[[@B10]\]. All participants provided written informed consent, as reported by Roessler et al. \[[@B10],[@B11]\].

Data extraction and end points {#sec2-2}
------------------------------

We extracted the GSE14520 microarray expression profile. Tumor sample and microarray processing were reported by Roessler et al. \[[@B10],[@B11]\] and are available at <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520>. The experiment protocols and data processing methods are available at <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM362949>. Siglec gene expression levels were calculated using the matchprobes package in the R program and the log2 RMA-calculated signal intensity was reported. Nine siglecs including siglec-1, siglec-2, siglec-3, siglec-4, siglec-5, siglec-6, siglec-7, siglec-8 and siglec-9 were searched and included in our analysis. Overall survival (OS) was defined as the time from surgery to death from any disease.

Statistical analysis {#sec2-3}
--------------------

PASW Statistics software version 22.0 from SPSS Inc. (Chicago, IL, USA) was used for statistical analysis. Student's *t*-test, Mann--Whitney *U*-test and Chi-squared test were used for normally distributed continuous data, non-normally distributed continuous data and categorical variables, respectively. Univariate analysis and multivariate Cox and logistic regression were assessed for identifying factors associated with OS and clinico-pathological features. The Kaplan--Meier curve by log rank method was used to compare OS between different groups. A two-tailed *P* \< 0.05 were considered statistically significant.

Results {#sec3}
=======

Siglec levels comparison between tumor and non-tumor tissues {#sec3-1}
------------------------------------------------------------

Nine members of siglec family were identified, including siglec-1 to siglec-9. As shown in [Figure 1](#F1){ref-type="fig"}, all siglecs were overexpressed in non-tumor tissues compared with those in tumor tissues (all *P* \< 0.05, [Figure 1](#F1){ref-type="fig"}).

![Differential expression of siglecs between non-tumor and tumor tissues in HCC patients](bsr-38-bsr20181423-g1){#F1}

Relationship between siglecs and HCC overall survival {#sec3-2}
-----------------------------------------------------

As shown in [Table 1](#T1){ref-type="table"}, univariate analysis showed that siglec-2 and siglec-4 were potential factors associated with HCC OS (*P* = 0.065 and *P* = 0.061, respectively). When all siglecs were evaluated by a multivariate model using enter selection, up-regulation of siglec-2 in tumor tissues showed protective potentials for HCC OS (HR = 0.883, 95%CI = 0.806--0.966, *P* = 0.007). In contrast, siglec-4 overexpression was negatively associated with HCC OS (HR = 1.059, 95%CI = 1.025--1.094, *P* = 0.001).

###### Univariate and multivariate Cox regression analysis of siglecs and HCC overall survival

  Siglecs, per increase of 1 unit   Univariate analysis    Multivariate analysis                          
  --------------------------------- ---------------------- ----------------------- ---------------------- -------
  Siglec-1                          0.988 (0.971--1.006)   0.18                                           
  Siglec-2                          0.932 (0.65--1.004)    0.065                   0.883 (0.806--0.966)   0.007
  Siglec-3                          1.005 (0.979--1.032)   0.708                                          
  Siglec-4                          1.028 (0.999--1.058)   0.061                   1.059 (1.025--1.094)   0.001
  Siglec-5                          1.025 (0.968--1.084)   0.397                                          
  Siglec-6                          0.995 (0.911--1.087)   0.917                                          
  Siglec-7                          1.003 (0.94--1.07)     0.939                                          
  Siglec-8                          1.018 (0.898--1.153)   0.783                                          
  Siglec-9                          1.004 (0.864--1.167)   0.957                                          

Furthermore, we performed *R* software analysis to determine the cut-off values of siglec-2 and siglec-4 for the prediction of OS in the training set. Then, we transformed the continuous data above into dichotomous variables according to the determined cut-off values. Unfortunately, no statistical significance was found between siglec-4 and HCC OS in training set based on randomized sampling. According to *R* language analysis, we grouped siglec-2 using cut-off values of 11.6 into siglec-2 low group and siglec-2 high group. This demonstrated that patients in siglec-2 high group had better OS than those in siglec-2 low group, both in training set and validation set (log rank *P* = 0.041 and log rank *P* = 0.031, respectively, [Figure 2](#F2){ref-type="fig"}A,B). When all HCC patients were included in the Kaplan--Meier event analysis, patients with higher siglec-2 levels achieved longer OS months than those with lower siglec-2 levels (mean survival months in siglec-2 high group = 50.9 ± 1.8 and in siglec-2 low group = 41.5 ± 3.9, respectively, log rank *P* = 0.01, [Figure 2](#F2){ref-type="fig"}C).

![Association between siglec-2 expression and OS in HCC patients\
Higher siglec-2 levels are associated with better OS in HCC patients, in training set (**A**), validation set (**B**) and total database (**C**).](bsr-38-bsr20181423-g2){#F2}

Relationship between siglecs and HCC clinico-pathological features {#sec3-3}
------------------------------------------------------------------

We grouped HCC patients with siglec-2 cut-off of 11.6 and compared differences of clinico-pathological features between these two groups. As shown in [Table 2](#T2){ref-type="table"}, more patients had higher alpha-fetoprotein (AFP) levels in siglec-2 low group than those in siglec-2 high group (60% vs. 41.7%, *P* = 0.043). Additionally, no differences were found in patients' clinico-pathological features including HBV virus status, ALT levels, tumor size, multinodular, cirrhosis and tumor staging (all *P* \> 0.05).

###### Clinico-pathological features based on siglec-2 expression in HCC patients

  Clinico-pathological features          High siglec-2 group (*n* = 180)   Low siglec-2 group (*n* = 40)   *P* value
  -------------------------------------- --------------------------------- ------------------------------- -----------
  Gender (male/female), *n*              156/24                            34/6                            0.781
  Age (\>50 years/\<50 years), *n*       99/81                             25/15                           0.387
  HBV viral status (AVR-CC/no/NA), *n*   47/128/5                          9/27/4                          0.111
  ALT (\>50/\<50/NA), U/l                76/104                            14/26                           0.401
  Main tumor size (\>5/\<5/NA), cm       66/114/0                          14/25/1                         0.104
  Multinodular (yes/no), *n*             37/143                            7/33                            0.662
  Cirrhosis (yes/no), *n*                163/17                            39/1                            0.147
  TNM staging (I--II/III/NA), *n*        138/40/2                          31/8/1                          0.763
  BCLC staging (0-A/B-C/NA), *n*         138/41/1                          30/9/1                          0.503
  CLIP staging (0/1/2/3/4/5/NA), *n*     81/61/25/8/2/1/2                  15/13/9/1/1/0/1                 --
  AFP (\>300/\<300/NA), ng/ml            75/102/3                          24/16/0                         0.043

AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AVR-CC, active viral replication chronic carrier; NA, not available.

We performed logistic regression analysis to identify the relationship between siglecs and HCC clinico-pathological features. This was summarized in [Table 3](#T3){ref-type="table"}. Univariate analysis showed that siglec-2 was a potential factor associated with AFP levels in HCC patients (*P* = 0.012). When all siglecs were evaluated by a multivariate model using enter selection, siglec-2 overexpression is negatively associated with HCC patients' AFP level (OR = 0.822, 95%CI = 0.724--0.934, *P* = 0.003). To evaluate the predictive accuracy of siglec-2 and siglec-4 for AFP levels in HCC patients, we analyzed ROCs and found that elevated siglec-2 significantly and accurately predicted lower AFP level (AUC = 0.607, *P* = 0.007, [Figure 3](#F3){ref-type="fig"}).

![ROC curve of siglec-2 for AFP \> 300 ng/ml](bsr-38-bsr20181423-g3){#F3}

###### Relationship between siglecs and HCC clinico-pathological characteristics by logistic regression analysis

  Siglecs, per increase of 1 unit   AFP \> 300 ng/ml                                      
  --------------------------------- ---------------------- ------- ---------------------- -------
  Siglec-1                          1.001 (0.984--1.018)   0.936                          
  Siglec-2                          0.891 (0.815--0.975)   0.012   0.822 (0.724--0.934)   0.003
  Siglec-3                          1.0 (0.967--1.035)     0.992                          
  Siglec-4                          1.034 (0.969--1.102)   0.313                          
  Siglec-5                          1.028 (0.944--1.12)    0.523                          
  Siglec-6                          1.045 (0.932--1.173)   0.449                          
  Siglec-7                          1.044 (0.959--1.137)   0.316                          
  Siglec-8                          1.063 (0.908--1.245)   0.448                          
  Siglec-9                          0.861 (0.714--1.038)   0.117                          

Siglec-2 coexpression genes and pathways enrichment {#sec3-4}
---------------------------------------------------

Using the GSE14520 microarray database, coexpressed genes of siglec-2 in HCC were searched in HCC. As shown in [Table 4](#T4){ref-type="table"}, 137 genes were found to be positively coexpressed with siglec-2. On the other hand, 352 genes were negatively coexpressed with siglec-2 as shown in [Table 5](#T5){ref-type="table"}.

###### Siglec-2 positive coexpressed genes (*n* = 137)

  ----------- -------------- ---------- --------- ----------- -------------- --------- --------- ---------- --------
  ACADS       TG             PLCB2      NNAT      LCAT        GNAO1          VIPR1     CD79A     GPR162     MYLPF
  RIN1        ESR1           RCE1       SULT2B1   TCP11L1     MYOM2          CD33      LLGL1     WNT10B     PRKCG
  ADCYAP1     NPHP1          ELAVL3     SCN2A     CACNG3      PDE3A          KLKB1     INSL4     F11        MYOD1
  UMOD        CUBN           NAT2       ADRB3     NGF         STATH          IL11      HTR6      AKAP4      CHRND
  LTK         SLC6A13        NOS1       KCNS1     POU6F2      CRYGD          SLC28A1   FOXH1     CRYBB3     CACNB4
  PRMT8       CD160          SCN7A      BMP8B     MYBPC3      PSD            GIPR      OSBPL7    RASGRP2    BMP3
  CYP2A13     GLP1R          SLC14A2    GJA8      EYA2        CORO2B         PDE6G     CHRNA3    NR6A1      CLEC4M
  TACR1       GRIN1          ADRA1D     BMP7      DSCAM       TUBB7P         CAMK2A    SH3BP1    GPD1       MYOZ3
  PRSS53      FSHB           GPR182     PLAC4     TOM1L2      EMX1           CFAP74    DNAH2     CFAP70     MYCNOS
  CYP2A7P1    LOC101929073   DDR1-AS1   KLK1      LINC01482   GRIK5          FUT7      CNPY4     TTC38      ECHDC2
  A4GALT      MYOZ1          NLGN3      CPLX3     SLC13A4     RNF122         RETN      CARD14    KCNQ1DN    NOX5
  LINC00652   PLA2G3         THEG       CTNNA3    GABRQ       CHST8          GSN-AS1   C7orf69   CLDN17     HOXC8
  ZNF717      FGF17          TAS2R7     IL36A     OR1D2       MYL10          LZTS1     CLEC4A    KIAA1644   LRCH4
  DMWD        ADRBK1         PNPLA2     ACACB     CACNG4      LOC100505915   NPEPL1                         
  ----------- -------------- ---------- --------- ----------- -------------- --------- --------- ---------- --------

###### Siglec-2 negative coexpressed genes (*n* = 352)

  --------- ----------- --------- ---------- ----------- --------- --------- --------- ---------- --------- ----------- ----------
  EIF4G2    RPS5        CBX3      ZNF146     ILF2        RPL30     RPL37     HNRNPU    NCL        CLTC      PTGES3      YWHAZ
  PHB       DYNLL1      MAPRE1    CAPRIN1    RPS27       GNB1      RAN       HNRNPC    CALU       RPLP1     LAMC1       XRCC6
  SNRPD2    ZNF207      CCT4      SSR1       CCT3        DEK       IPO7      ACTR3     YWHAH      EIF5B     RPS18       TUBA1B
  ARF4      CSE1L       ACLY      SSB        UBA2        PSMD1     PCNA      CAPZA2    PSMC4      RPS16     SRP9        TOP2A
  PPIA      CCT6A       UBE2D2    YME1L1     TPD52L2     PPP1CB    BUB3      VBP1      RRM1       RCN2      TOMM70A     CBX1
  UBE2N     RPA1        TRIP12    MCM3       NME1        SEC23B    PPP4R1    ZC3H15    PWP1       ACP1      ITGA6       ARL1
  SMC4      MARCKS      PSMC6     TUBG1      CDC123      WSB2      ADNP      VPS26A    NET1       HDAC2     RRM2        CKS1B
  UBE2A     MCM6        CPD       CCT2       RSU1        KIF5B     MORF4L2   LANCL1    DPF2       PRPF4B    PPP1R2      VEZF1
  NUP133    SRPK1       STT3A     EIF3M      PSMB4       CDK4      VPS72     STAG1     SMARCA5    ACBD3     UBE2K       PSMD12
  USP1      CPSF6       H2AFV     KIAA0101   GMFB        HSPA13    TYMS      SSBP1     HTATSF1    TOPBP1    NRAS        LPGAT1
  ACTL6A    GTF2A2      SNRPD1    UBE2S      PIGC        CDC20     SRSF3     HLTF      TXNDC9     DNM1L     HAT1        SRPK2
  CDK1      MAPK9       HS2ST1    SNRPE      PPP2R5E     RBBP8     EZH2      PSMA4     MFAP1      SUCO      RPP30       SEC61G
  STAM      PTTG1       CD2AP     RTCA       COIL        RFC2      UTP18     TRIP4     C5orf22    TDG       BUB1B       SNRPF
  RFC4      ZWINT       CKS2      DBF4       CEP350      PPM1D     IARS      FEN1      EEF1E1     VRK2      HNRNPA2B1   SRP19
  PFDN4     SNRPG       KIN       SLBP       GINS1       NUP155    MFN1      NIPBL     CAND1      NCKAP1    NUP62       RBM3
  CLIC1     RPN2        RPS3      PRKDC      ARPC3       YWHAB     NAP1L1    HNRNPR    PSMD11     MRPL3     HMGB2       PTK2
  POLE3     CANX        STK24     TXN        ILF3        PRCC      SEPHS1    BECN1     DNAJB6     ABI1      SF3B4       GLRX3
  UFD1L     DR1         FAM208A   SWAP70     SLC35A2     POLR3C    BAG2      MSH2      EED        MRPL9     SOCS5       CHUK
  PRKCI     CDKN3       PHTF2     HMGN4      CNPY2       UBE2E3    TPX2      NOL7      HSP90AA1   PSMD4     CACYBP      PDCD10
  MCM7      HSPA4       CDK7      COX11      TUBA1C      KPNA2     HSPA5     ITGB1     SMARCE1    RPL7      U2SURP      LSM14A
  RBM12     ANKLE2      NUP205    WAPL       SERPINB1    MAPK1     PSMD14    CLASP2    GNS        DESI2     KIAA0368    SNRNP27
  AVL9      UBE2E1      NEK7      AQR        MAPK1IP1L   KDM3A     NUP160    ATF2      TRIM37     DNAJC9    SP3         SNRPB
  RHEB      TUBB3       H2AFZ     HSP90AB1   GMPS        RALA      H2AFY     SUB1      RIF1       CCNB1     SNW1        SUMO4
  CLTA      MIR1244-3   PDIA6     HN1        ALDH18A1    UFC1      ENAH      SYNCRIP   PRELID3B   CDC27     DYNLRB1     MRPL42
  SAE1      CNOT6       MORF4L1   ASNSD1     PRC1        NUP85     NUSAP1    PRPF40A   AGFG1      MRPS10    ARMC1       GOLT1B
  TMEM258   GTPBP4      MEX3C     CKAP2      MAP4K3      FAM208B   PFDN2     GMNN      RIOK2      MRS2      LYRM4       DUSP12
  CDC73     DTL         HEATR1    NUP37      NXT1        IFT52     CNIH4     NUP107    RPAP3      PPP2R3C   RPS6KC1     TMEM106B
  TPRKB     RRP15       HSPA14    TMEM185B   OLA1        PSMD10    UXS1      ECT2      UCHL5      SAP130    NAA35       ARID4B
  LYRM2     TBL1XR1     ARPP19    ANP32E     DENR        MED17     PRPF18    METTL5    DDX50      ADSS      SEH1L       NOL11
  PAPOLA    MCM4        RACGAP1   THOC2                                                                                 
  --------- ----------- --------- ---------- ----------- --------- --------- --------- ---------- --------- ----------- ----------

Additionally, gene set enrichment analysis (GSEA) was used for identification of putative KEGG pathways associated with siglec-2 coexpressed genes. Consequently, pathways including MAPK signaling pathway and calcium signaling pathway, which have been proved in liver cancer, were significantly enriched with siglec-2 positively coexpressed genes (*FDR* \< 0.05, [Figure 4](#F4){ref-type="fig"}), While siglec-2 with its negatively coexpressed genes contributed to tumor cell phenotype including cell cycle, spliceosome, DNA replication, ubiquitin-mediated proteolysis, proteasome, oocyte meiosis, mismatch repair, ribosome, pathways in cancer and pathogenic *Escherichia coli* infection (*FDR* \< 0.05, [Figure 5](#F5){ref-type="fig"}).

![KEGG functional enrichment of siglec-2 with its positive coexpressed genes](bsr-38-bsr20181423-g4){#F4}

![KEGG functional enrichment of siglec-2 with its negative coexpressed genes](bsr-38-bsr20181423-g5){#F5}

Discussion {#sec4}
==========

Immunotherapy for HCC has shown some success \[[@B7]\]. However, in most HCC patients or animal models, tumors progressed in spite of tumor-specific immune responses \[[@B12]\]. Thus, to find new immune markers of HCC development is still of significant importance. Functionally, siglecs participate in regulating the innate and adaptive immune responses through the recognition of their glycan ligands \[[@B13]\]. They have been demonstrated to be involved in a series of inhibitory processes, cell--cell interaction processes and endocytosis \[[@B8],[@B14]\]. In our analysis, we found that all siglecs including siglec-1 to siglec-9 were significantly suppressed in HCC tumors, which may serve as anti-oncogenes. Recently, several studies revealed that siglec deficiencies contributed to the potential for generation of malignancy like lymphomas and leukemias \[[@B17],[@B18]\]. As reviewed by Macauley et al., siglecs played a role in regulating of immune surveillance of cancer by keeping with their roles aiding immune cells in distinguishing between self and non-self \[[@B13]\]. They concluded that siglecs effectively reduce innate immune responses against cancer cells by down-regulating immune cells that express them through recognition of sialoside ligands on the cancer cell itself or soluble mucins produced by the cancer cell \[[@B13]\].

Serum AFP levels increase by 20--80% in HCC patients and are strongly associated with tumor aggressiveness \[[@B19]\]. High level of AFP is correlated with tumor size, vascular invasion and poorly differentiated HCC \[[@B19],[@B22],[@B23]\]. In our analysis, we found that siglec-2 expression in tumor tissues was significantly negatively associated with AFP elevation. Although the immunogenicity of AFP is weak, it could induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells and T lymphocytes \[[@B24],[@B25]\]. Several studies demonstrated that AFP is involved in immunosuppression \[[@B25],[@B26]\]. It can impair the function of macrophages leading to decreased phagocytosis and impaired antigen-presenting abilities \[[@B27]\]. AFP-modified immune cell vaccine or peptide vaccine has displayed the specific antitumor immunity against AFP-positive tumor cells \[[@B28],[@B29]\]. Hence, siglec-2 could play antitumor effects via enhancing immune responses by inhibition AFP levels. Although the proportion of patients with elevated AFP in siglec-2 low expression group was significantly higher than that in siglec-2 high expression group (60.0% vs. 41.7%), the biologic value is not strong. Further research with larger samples are needed.

Our results also showed that siglec-2 elevation predicts better survival in HCC. Siglecs including siglec-2 have been reported to regulate cell growth and survival, by both inhibition of proliferation and/or induction of apoptosis \[[@B13]\]. Throughout the last decade, several novel therapeutic agents that target siglec-2 are being developed as an alternative approach for cancer treatment \[[@B17],[@B18],[@B30]\]. Previous reports showed that siglec-2 as a B-cell-associated adhesion protein appeared to play a critical role in establishing signaling thresholds for B-cell activation, mediating normal antibody response to thymus-independent antigens and regulating the lifespan of mature B cells \[[@B31],[@B32]\]. Therefore, down-regulating of siglec-2 in tumor tissues might risk the tumor progress by reducing innate immune response and mature B cells proliferation in HCC patients. Recently, it is gradually recognized that some B-cell subpopulations including regulatory B cells can impair CD4^+^ T cell activation or produce cytokines promote tumor progression \[[@B33]\], Leading to dramatically suppress antibody and inhibit antitumor effector T cells \[[@B34],[@B36]\]. Lymphotoxin secreted from tumor-infiltrating B cells also promotes tumor growth \[[@B37]\]. Therefore, serves as B cell receptor inhibitor, siglec-2 might suppress tumor progress and development, contributing to a prolonging survival in HCC patients. Additionally, we enriched coexpressed genes of siglec-2 and its functional pathways. Siglec-2 and its coexpressed genes participant in the tumor cell phenotype including cell cycle, spliceosome, DNA replication, ubiquitin mediated proteolysis, proteasome, mismatch repair and pathways in cancer like MAPK signaling pathway and calcium signaling pathway, which should be the main research directions of siglec-2 mechanism in HCC in future.

Although siglec-4 levels in tumor tissues might associate with HCC OS in our Cox regression analysis, no significance was found in log-rank methods. Known as myelin-associated glycoprotein (MAG), siglec-4 is selectively localized in periaxonal Schwann cell and oligodendroglial membranes of myelin sheaths \[[@B38]\] and plays a role in axon-myelin stabilization and inhabitation of axon regeneration after injury \[[@B39],[@B40]\]. Since siglec-4 is only found in the nervous system, even though siglec-4 showed some significance for HCC OS in our analysis, deep research of this gene in HCC development should be cautious and well-designed.

The present study has some limitations: First, our research was a preliminary analysis from GEO database, no further mechanism data were shown. Second, we included siglecs as a continuous variable in the logistic and Cox regression process, leading to a small HRs of the siglecs biomarker candidates. Third, only siglec-1 to siglec-9 were included in this analysis, other siglec family members like siglec-10 to siglec-15 were not available in this gene database. Fourth, we did not conduct mechanism research in siglec-2 protein level. Even with these limitations, the results might provide useful insights for HCC research in therapeutic strategy.
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